What is Celecoxib? Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities. Developed in the late 1990s and approved by the US FDA in 1999 under the brand name Celebrex, it was the first selective cyclooxygenase-2 (COX-2) inhibitor to reach the market. It is widely used to manage pain and inflammation associated with various forms of arthritis and acute pain conditions. By selectively targeting the COX-2 enzyme, Celecoxib was designed to provide the therapeutic benefits of traditional non-selective NSAIDs (like ibuprofen and naproxen) while reducing the incidence of gastrointestinal complications, such as ulcers and mucosal bleeding, which are common with non-selective agents. Mechanism of Action Nonsteroidal anti-inflammatory drugs exert their therapeutic effects primarily by inhibiting cyclooxygenase (COX) enzymes, which catalyze the conversion of arachidonic acid to prostaglandins—key mediators of pain, inflammation, and fever. There are two primary COX isoforms: COX-1 and COX-2. COX-1 is constitutively expressed in most tissues and is involved in physiological functions, such as maintaining the gastric mucosal barrier, regulating renal blood flow, and facilitating platelet aggregation. COX-2, conversely, is inducible and is expressed primarily at sites of tissue injury and inflammation, where it produces prostaglandins that mediate pain and inflammatory responses. Celecoxib is a diaryl-substituted pyrazole that selectively inhibits the COX-2 isoform at therapeutic concentrations. It has a high selectivity for COX-2 over COX-1, which allows it to reduce prostaglandin synthesis at sites of inflammation while sparing the COX-1-mediated cytoprotective prostaglandins in the stomach. At therapeutic doses, Celecoxib does not inhibit platelet aggregation, which is a COX-1-mediated process dependent on thromboxane A2. Pharmacokinetics & Metabolism Following oral administration, Celecoxib is absorbed, with peak plasma concentrations (Cmax) achieved within 3 hours post-dose under fasting conditions. Absolute bioavailability has not been fully determined but is estimated to be high. When taken with a high-fat meal, the absorption of Celecoxib is delayed, with Tmax increased by 1 to 2 hours, and total absorption (AUC) increased by approximately 10% to 20%. It is highly bound to human plasma proteins (approximately 97%), primarily to albumin, and is widely distributed throughout body tissues. Celecoxib is metabolized primarily in the liver by the cytochrome P450 enzyme CYP2C9. The primary metabolites are inactive and are excreted in both feces (57%) and urine (27%). The elimination half-life of Celecoxib is approximately 11 hours (range 8 to 15 hours), making it suitable for once- or twice-daily dosing. In patients with moderate hepatic impairment (Child-Pugh Class B) or in patients who are poor metabolizers of CYP2C9, plasma concentrations of Celecoxib are significantly increased, requiring dose reductions. Clinical Indications & Dosage Celecoxib is clinically indicated for: Relief of the signs and symptoms of Osteoarthritis (OA) Relief of the signs and symptoms of Rheumatoid Arthritis (RA) Relief of the signs and symptoms of Ankylosing Spondylitis (AS) Management of acute pain in adults Treatment of primary dysmenorrhea (menstrual pain) For osteoarthritis, the standard dosage is 200 mg taken orally once daily or split as 100 mg twice daily. For rheumatoid arthritis, the standard dosage is 100 mg to 200 mg twice daily. For acute pain and dysmenorrhea, the recommended dose is 400 mg initially, followed by an additional 200 mg if needed on the first day, and 200 mg twice daily as needed on subsequent days. In patients with moderate hepatic impairment, the daily dose of Celecoxib should be reduced by 50%. Warnings & Safety Profile Like all NSAIDs, Celecoxib carries specific warnings and precautions, particularly regarding cardiovascular and gastrointestinal safety: Cardiovascular Risk: Selective COX-2 inhibitors may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use or in patients with pre-existing cardiovascular disease. Celecoxib is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Gastrointestinal Risk: Although selective COX-2 inhibition reduces the risk of gastrointestinal ulcers and bleeding compared to non-selective NSAIDs, serious GI events can still occur at any time during therapy. Risk factors include advanced age, concurrent use of oral corticosteroids or anticoagulants, smoking, alcohol use, or a history of peptic ulcer disease. Renal Effects: Long-term administration of Celecoxib can lead to renal papillary necrosis and other renal injury. It should be used with caution in patients with pre-existing renal disease, heart failure, or dehydration, and renal function should be monitored regularly. Frequently Asked Questions Is Celecoxib safer for the stomach than ibuprofen? Yes, clinical trials have shown that Celecoxib is associated with a significantly lower rate of upper gastrointestinal ulcers and complications compared to traditional non-selective NSAIDs like ibuprofen or naproxen. However, the risk is not zero, and caution is still advised for high-risk patients. Can I take Celecoxib if I have a sulfa allergy? No. Celecoxib contains a sulfonamide moiety and is contraindicated in patients with a history of allergic-type reactions to sulfonamides (sulfa drugs). It can cause severe skin reactions, such as Stevens-Johnson syndrome, in these patients.